GSK (GSK) is a Healthcare company in the Drug Manufacturers General industry. It has a market capitalization of $100.88B, a trailing price-to-earnings ratio of 10.6 and a free-cash-flow yield of 6.2%. Over the most recent reported fiscal year, revenue grew 4.1% and free cash flow per share grew 34.0%. Nama's AI scorecard rates it Buy, 6.5 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Buy · 6.5/10
Positive, at the low end of Buy. As of Nov 7, 2026.
Momentum
Lagging · -0.2% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-18.4%
How far the last close sits under the highest price of the past five years.
Market cap
$100.88B
Trailing P/E
10.6
Price / book
8.0
Price / sales
2.2
FCF yield
6.2%
Dividend yield
3.6%
Gross margin
72.6%
Operating margin
19.1%
Net margin
13.0%
Revenue growth (YoY)
+4.1%
Revenue growth (3-yr annual)
+3.7%
EPS growth (YoY)
+13.3%
FCF/share growth (YoY)
+34.0%
Beta
0.3
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers General
GSK earnings
Next report: Feb 3, 2027 (Q4 2026, EPS estimate $0.74).
Beat the EPS estimate in 4 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Oct 27, 2026
$1.45
$1.33
+9.0%
$11.93B
Q2 2026
Jul 28, 2026
$1.34
$1.25
+7.2%
$11.28B
Q1 2026
Apr 29, 2026
$1.26
$1.16
+8.6%
$10.24B
Q4 2025
Feb 4, 2026
$0.70
$0.62
+12.9%
$11.56B
GSK analyst price target
Median target $58.00 from 9 analysts, ranging $49.00 – $70.00.
Nama's AI scorecard currently rates GSK Buy (6.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is GSK's P/E ratio?
GSK trades at a trailing price-to-earnings ratio of 10.6.
When does GSK report earnings?
GSK's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $0.74.
What is the GSK price target?
The median analyst price target from 9 analysts is $58.00, with a range of $49.00 – $70.00.
Is GSK Shariah compliant?
Nama's AAOIFI-style screen reads GSK as Not Shariah Compliant. At least one of the three ratios or the industry test failed.